Merck KGaA/€MRK
1D1W1MYTD1Y5YMAX
Capital at risk
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
- Ticker
- €MRK
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 62,136
- Headquarters
- Darmstadt, Germany
- Website
- www.emdgroup.com
Merck KGaA Metrics
BasicAdvanced
€59B
24.62
€5.45
0.81
€2.20
1.64%
Price and volume
Market cap
€59B
Beta
0.81
52-week high
€148.60
52-week low
€100.70
Average daily volume
228K
Dividend rate
€2.20
Financial strength
Current ratio
1.695
Quick ratio
0.988
Long term debt to equity
37.006
Total debt to equity
40.618
Dividend payout ratio (TTM)
43.80%
Interest coverage (TTM)
9.08%
Profitability
EBITDA (TTM)
5,587
Gross margin (TTM)
59.09%
Net profit margin (TTM)
11.21%
Operating margin (TTM)
17.61%
Effective tax rate (TTM)
21.35%
Revenue per employee (TTM)
€340,000
Management effectiveness
Return on assets (TTM)
4.65%
Return on equity (TTM)
8.13%
Valuation
Price to earnings (TTM)
24.621
Price to revenue (TTM)
2.759
Price to book
1.93
Price to tangible book (TTM)
14.04
Price to free cash flow (TTM)
22.62
Free cash flow yield (TTM)
4.42%
Free cash flow per share (TTM)
5.932
Dividend yield (TTM)
1.64%
Forward dividend yield
1.64%
Growth
Revenue change (TTM)
-0.40%
Earnings per share change (TTM)
-17.27%
3-year revenue growth (CAGR)
-1.42%
10-year revenue growth (CAGR)
4.16%
3-year earnings per share growth (CAGR)
-8.35%
10-year earnings per share growth (CAGR)
5.48%
10-year dividend per share growth (CAGR)
7.68%
What the Analysts think about Merck KGaA
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Analyst projections of the future price of Merck KGaA stock.
Bulls say / Bears say
Merck KGaA raised its 2026 core EBITDA guidance to €5.9–6.3 billion (from €5.7–6.1 billion) and net sales guidance to €21.0–21.8 billion, driven by robust Q2 performance and easing foreign exchange headwinds (Euronext) (Merck Q2 release)
Merck KGaA’s Semiconductor Solutions unit delivered 17.3% organic sales growth in Q2 2026, driven by AI-related demand, while the Electronics division’s EBITDA pre rose organically by 87.5%, underlining strong margin expansion (Merck Q2 release) (Reuters)
Merck KGaA agreed to acquire Bio-Techne for $73 per share (enterprise value ~$11.3 billion), strengthening its Life Science portfolio in multi-omics, spatial biology and advanced therapeutics to drive long-term growth (Investing.com) (Merck Q2 release)
Healthcare sales fell 3.4% year-on-year in Q2 2026 and Healthcare EBITDA pre declined 4.6%, signaling margin pressure in its core pharmaceutical segment (Investing.com) (Merck Q2 release)
The multiple sclerosis drug Mavenclad will generate no U.S. sales from August 2026 due to generic competition, eliminating a key revenue contributor three months later than initially anticipated (Reuters) (Merck Q2 release)
Merck KGaA forecast adjusted operating profit to decline by up to 4% in 2026, excluding currency effects, reflecting earnings pressure from generics and external headwinds (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Merck KGaA Financial Performance
Revenues and expenses
Merck KGaA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Merck KGaA
AllEURGBPUSD
Fund name | Fund size | €MRK weighting |
|---|---|---|
iShares Dax ESG€EXIA | €127M | 1.73% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 1.12% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 1.12% |
iShares Core DAX€EXS1 | €8.6B | 1.07% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 1.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.